GET DAILY SIGNALSImmunityBio (IBRX): Analyst Targets Point to +62% Upside to $14
Key Takeaways
- The central $14 target is the arithmetic mean of four current analyst price targets ($12, $14, $15 and $16), rounded from a calculated average of $14.25.
- At a recent closing price of $8.64, reaching $14 would require a gain of roughly 62%, a very large move even for a high-volatility biotech.
- The analyst range is relatively tight at $12 to $16, reflecting broad agreement on a "Strong Buy" or "Buy" view but also meaningful uncertainty about near-term execution.
- The strongest support is commercial momentum for Anktiva and a growing list of regulatory approvals, including an FDA label expansion announced in October 2026.
- The biggest risks are a third-quarter revenue miss, a going-concern warning from management, and the company's continued reliance on external financing.
- For more context, explore Major News, Today's Price Move, the Forecast page, and Earnings details.
- Readers can also explore Trending AI Robots for additional AI-driven market analysis.
Analyst Price Targets and Consensus View
ImmunityBio, Inc. (IBRX) is a San Diego-based clinical-stage immunotherapy company whose lead product, Anktiva (nogapendekin alfa inbakicept), is approved to treat certain forms of bladder cancer. The central $14 target reflects four current analyst price targets gathered from S&P Global and Yahoo Finance data: BTIG at $12 (maintained October 30, 2026), Jefferies at $14 (raised from $12 on October 14, 2026), H.C. Wainwright at $15 (reiterated October 15, 2026), and Piper Sandler at $16 (raised from $12 on October 14, 2026). The arithmetic mean of these four targets is $14.25, which rounds to the $14 central target used here, with a low-to-high range of $12 to $16.
All four firms carry Buy-equivalent ratings, and the broader consensus is characterized as "Strong Buy." The recent target increases from Jefferies and Piper Sandler followed the FDA's decision to expand Anktiva's approved indication to include BCG-unresponsive non-muscle-invasive bladder cancer with papillary-only tumors. It is important to note that most of these targets were set before the company's third-quarter earnings report, which could prompt downward revisions. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
At a recent close of $8.64, IBRX trades near the middle of a 52-week range of $1.95 to $12.43, with a market capitalization of roughly $9.2 billion. Reaching $14 would require an advance of about 62% from that level, a very large move. The stock has delivered an extraordinary run, gaining more than 300% over the trailing year, but it pulled back sharply after third-quarter results showed revenue of $48.84 million versus a consensus near $59.2 million and a wider-than-expected adjusted loss.
The path toward the target depends heavily on whether Anktiva's commercial ramp resumes its prior trajectory. Revenue has grown rapidly, with Q2 2026 revenue of $51.2 million up about 94% year over year, and management has pointed to an eighth consecutive quarter of sequential product growth. Continued label expansion, international launches, and progress in the Phase 3 QUILT-2.005 trial could all support a higher valuation, but the stock remains unprofitable and trades on forward revenue rather than earnings.
What Could Support a Move Toward the Target
Several verified developments underpin the bullish case. In October 2026 the FDA broadened Anktiva's label to include papillary-only tumors, meaningfully expanding the addressable patient population. The company also reported that Anktiva combined with BCG met the primary endpoint of the QUILT-2.005 Phase 3 trial in BCG-naïve patients, with plans to seek approval by year-end. Internationally, Anktiva has received authorizations across more than 30 countries, including Saudi Arabia, the United Arab Emirates, and Israel, and an Irish subsidiary supports a planned European launch. A PDUFA decision on a further label expansion is expected in early January 2027.
What Could Prevent the Target From Being Reached
The principal obstacles are financial. Third-quarter revenue missed estimates for the first time in six quarters, and management included a going-concern disclosure citing substantial doubt about its ability to continue without additional financing or related-party support. Total liabilities were reported near $1.75 billion, with roughly $334 million in cash, equivalents, and marketable securities at quarter-end. The company has also used an at-the-market (ATM) offering program, which can dilute shareholders. Insider selling under pre-arranged plans and the wide gap between a $9 billion-plus market value and limited current revenue add further uncertainty. A securities class-action lawsuit has also been filed, a common but notable overhang for a stock that has fallen sharply.
Technical Levels and Market Structure
Technically, IBRX sits just above its 200-day moving average near $7.96 but below its 50-day moving average near $8.74, a mixed picture following the post-earnings sell-off. The 52-week high of $12.43 stands between the current price and the $14 target and represents a meaningful resistance area. Below, the recent pre-market low near $7.37 and the round-number $7 zone mark near-term support. A decisive move back above the 50-day average could signal renewed momentum, while a break below the 200-day average would suggest the pullback has further to run. From what I see, this setup warrants close attention to volume and momentum indicators.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms may differ. Key upcoming items include the January 2027 FDA decision on further label expansion, the company's fourth-quarter earnings and revenue trajectory, any analyst target revisions following the Q3 miss, and announcements on financing, international launches, and the BCG-naïve regulatory filing. Signs of renewed Anktiva revenue acceleration and clarity on the company's capital position are the most important variables. I’m watching this closely as the next few quarters unfold.
Using AI Tools for Additional Insight
Tickeron's AI Daily Buy/Sell Signals provide a useful layer of analysis by monitoring market conditions and technical patterns across thousands of names. I find these signals helpful when evaluating volatile names like IBRX alongside traditional research.
Final Assessment
The $14 central target represents the average of four current analyst price targets, and it implies a roughly 62% gain from a recent price of $8.64. The bullish case rests on genuine momentum in Anktiva's label expansion, clinical data, and international rollout. The bearish case rests on a revenue miss, a going-concern disclosure, and financing risk. Analyst views are uniformly positive but clustered between $12 and $16, and the targets largely predate the disappointing third-quarter report. Whether IBRX reaches $14 will depend on whether commercial execution and regulatory milestones can overcome the company's near-term balance-sheet concerns; no outcome is guaranteed.
Exploring Tickeron AI Tools
In my own research process, I often turn to Tickeron’s AI Daily Buy/Sell Signals to cross-check technical setups and generate ideas across sectors. The platform scans market data in real time and highlights potential shifts, which can complement fundamental work on names like IBRX. It has become a regular part of how I monitor opportunities without replacing core analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
IBRX sees MACD Histogram crosses below signal line
IBRX saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 16, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 53 instances where the indicator turned negative. In 50 of the 53 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for IBRX moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In 17 of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at 85%.
IBRX moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for IBRX crossed bearishly below the 50-day moving average on October 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for IBRX entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 61 of 68 cases where IBRX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on IBRX as a result. In 78 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
Following a +12.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBRX advanced for three days, in 212 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
IBRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-8.744) is normal, around the industry mean (3.498). P/E Ratio (-9.089) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (47.847) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. IBRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 66 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a producer of cancer treatment products
Industry Biotechnology
Advertisement